Can Teladoc Prove the Short-Sellers Wrong in 2023?
Teladoc Health (NYSE: TDOC) is a pandemic darling that investors have soured on over the past year. Many believe it will no longer be a top growth stock as the economy returns to normal and people aren't stuck at home due to COVID-related restrictions.
Short-sellers have targeted the company and believe that even at a value of less than $4 billion, Teladoc's valuation could go even lower than it is right now. Are the short-sellers right, or is this a stock that can turn things around this year?
Early in 2020, telehealth looked like the future of healthcare and Teladoc was one of the hottest stocks to buy. As a result, short interest in the stock fell dramatically. But that trend has been reversing, and now that the excitement around Teladoc has cooled, more than 20% of the company's float is shorted:
Source Fool.com
